Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Explore the shared or separated neural mechanisms of social exclusion and social segregation and compare differential effects of AVP and OXT on these social interaction function.
A large body of research has shown that there are differences in the neural representation between social exclusion and social segregation, but the results are inconsistent, and the exploration of the neural basis is still insufficient. In addition, there are two mainstream theoretical explanations for these differences, namely the construction-level theory and the emotion-based theory, but there is no consistent theoretical model yet. Therefore, further exploration is necessary to confirm the cognitive and neural mechanisms underlying the differences between social exclusion and social segregation, and to attempt to reveal the theoretical explanations for these differences. In this project, the investigators propose to perform behavioral and functional magnetic resonance imaging (fMRI) techniques to examine the shared or separate neural mechanisms of social exclusion and social segregation (exp 1: social exclusion; exp 2: social separation) and investigate the modulatory effects of OXT/AVP on them (PLC/24IU OXT/20IU AVP).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intranasal Oxytocin | Active Comparator | Administer oxytocin (24 IU) intranasally. |
|
| Intranasal Arginine Vasopressin | Active Comparator | Administer Arginine Vasopressin (20 IU) intranasally. |
|
| Intranasal placebo | Placebo Comparator | Administer placebo intranasally. |
|
| Intranasal nothing (control) | No Intervention | Control condition |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intranasal Oxytocin | Drug | Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Neural index: OXT and AVP effects on fMRI based- social exclusion and social separation tasks | Comparions between OXT and AVP on social exclusion and social separation on brain activity or representations | 45 minutes after treatment administration |
| Behavioral index: behavioral ratings of social exclusion and social separation tasks | Comparions between social exclusion and social separation in pain ratings | Immediately after fMRI scanning |
Not provided
Not provided
Inclusion Criteria:
EXclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Keith M Kendrick, Dr | Contact | +86-28-61830811 | k.kendrick.uestc@gmail.com | |
| Weihua Zhao, Dr | Contact | +8618780247797 | zarazhao@uestc.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Siying Wang, Dr | University of Electronic Science and Technology of China | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Electronic Science and Technology of China(UESTC) | Recruiting | Chengdu | Sichuan | China |
Not provided
| ID | Term |
|---|---|
| D012934 | Social Isolation |
| D003919 | Diabetes Insipidus |
| ID | Term |
|---|---|
| D012919 | Social Behavior |
| D001519 | Behavior |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
Not provided
Not provided
Randomized placebo-controlled double-blind between-subject design
Not provided
Not provided
Not provided
| Intranasal Arginine Vasopressin | Drug | Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds. |
|
| Intranasal placebo | Drug | Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds. |
|
| D052776 |
| Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D010900 | Pituitary Diseases |
| D004700 | Endocrine System Diseases |